Lack of efficacy of standard doses of ivermectin in severe COVID-19 patients

Camprubí, DanielAlmuedo Riera, AlexMartí Soler, HelenaSoriano Viladomiu, AlexHurtado, Juan CarlosSubirà, CarmeGrau Pujol, BertaKrolewiecki, Alejandro J.Muñoz Gutiérrez, José2021-04-282021-04-282020-11-111932-6203https://hdl.handle.net/2445/176832Ivermectin has recently shown efficacy against SARS-CoV-2 in-vitro. We retrospectively reviewed severe COVID-19 patients receiving standard doses of ivermectin and we compared clinical and microbiological outcomes with a similar group of patients not receiving ivermectin. No differences were found between groups. We recommend the evaluation of high-doses of ivermectin in randomized trials against SARS-CoV-2.6 p.application/pdfengcc-by (c) Camprubí, Daniel et al., 2020http://creativecommons.org/licenses/by/3.0/esCOVID-19FarmacologiaCOVID-19PharmacologyLack of efficacy of standard doses of ivermectin in severe COVID-19 patientsinfo:eu-repo/semantics/article7104882021-04-28info:eu-repo/semantics/openAccess33175880